Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endothelial nitric oxide synthase (eNOS), also known as nitric oxide synthase 3 (NOS3), is an enzyme primarily responsible for the generation of nitric oxide (NO) in vascular endothelial cells. NO is a small, gaseous signaling molecule with critical roles in cardiovascular homeostasis, including vasodilation, inhibition of platelet aggregation, and regulation of vascular tone. Loss or dysfunction of eNOS leads to impaired vasodilation, increased risk for hypertension, thrombosis, inflammation, and atherosclerosis progression.
Catalyzes the conversion of L-arginine to L-citrulline and NO, leading to vasodilation, inhibition of platelet aggregation, and regulation of vascular tone.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nitric oxide synthase (endothelial) (eNOS).